Regeneron Pharmaceuticals (REGN) Liabilities and Shareholders Equity (2009 - 2026)

Regeneron Pharmaceuticals' Liabilities and Shareholders Equity history runs 18 years deep, the most recent figure standing at $40.9 billion for Q1 2026.

• On a quarterly basis, Liabilities and Shareholders Equity rose 8.85% year-over-year to $40.9 billion in Q1 2026; TTM through Mar 2026 was $159.8 billion, a 7.38% increase from a year earlier, with the FY2025 full-year figure at $40.6 billion, up 7.41% from the prior year.
• Liabilities and Shareholders Equity advanced to $40.9 billion in Q1 2026 per REGN's latest filing, from $40.6 billion in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $40.9 billion in Q1 2026 and bottomed at $26.3 billion in Q1 2022.
• The 5-year median for Liabilities and Shareholders Equity is $34.4 billion (2024), against an average of $34.1 billion.
• Across the five-year window, Liabilities and Shareholders Equity jumped 48.26% in 2022 and rose 5.91% in 2025, its largest moves.
• Year by year, Liabilities and Shareholders Equity stood at $29.2 billion in 2022, then advanced by 13.23% to $33.1 billion in 2023, then gained by 14.15% to $37.8 billion in 2024, then climbed by 7.41% to $40.6 billion in 2025, then gained by 0.76% to $40.9 billion in 2026.
• Per Business Quant, the three latest REGN Liabilities and Shareholders Equity figures stand at $40.9 billion (Q1 2026), $40.6 billion (Q4 2025), and $40.2 billion (Q3 2025).